{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Su Y"],"funding":["National Cancer Institute","NCI NIH HHS","National Institutes of Health"],"pagination":["795-804"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9477449"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(5)"],"pubmed_abstract":["<h4>Background</h4>Cytomegalovirus (CMV)-seropositive (R+) hematopoietic cell transplant (HCT) recipients have a survival disparity compared with CMV-seronegative recipient/donor (R-D-) pairs. We hypothesized that primary letermovir prophylaxis (LET) may abrogate this disparity. We investigated the relationship between LET and mortality at 1 year post-HCT.<h4>Methods</h4>In this retrospective cohort study, we included adult R-D- or R+ patients who received HCT pre-LET (between 1 January 2013 through 15 December 2017) and post-LET (between 16 December 2017 through December 2019). R+ were categorized by LET receipt as R+/LET or R+/no-LET. Cox proportional hazard models were used to estimate the association of LET with all-cause mortality at 1 year after transplantation.<h4>Results</h4>Of 848"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study."],"pmcid":["PMC9477449"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Tamari R","Karantoni E","Cho C","Nawar T","Jakubowski A","Zavras P","Han G","Papanicolaou G","Shaffer B","Perales MA","Su Y","Stern A","Dumke H","Giralt S"],"additional_accession":[]},"is_claimable":false,"name":"Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study.","description":"<h4>Background</h4>Cytomegalovirus (CMV)-seropositive (R+) hematopoietic cell transplant (HCT) recipients have a survival disparity compared with CMV-seronegative recipient/donor (R-D-) pairs. We hypothesized that primary letermovir prophylaxis (LET) may abrogate this disparity. We investigated the relationship between LET and mortality at 1 year post-HCT.<h4>Methods</h4>In this retrospective cohort study, we included adult R-D- or R+ patients who received HCT pre-LET (between 1 January 2013 through 15 December 2017) and post-LET (between 16 December 2017 through December 2019). R+ were categorized by LET receipt as R+/LET or R+/no-LET. Cox proportional hazard models were used to estimate the association of LET with all-cause mortality at 1 year after transplantation.<h4>Results</h4>Of 848","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T04:43:06.115Z","creation":"2025-04-19T04:43:06.115Z"},"accession":"S-EPMC9477449","cross_references":{"pubmed":["34979021"],"doi":["10.1093/cid/ciab1064"]}}